Robert D. Ciappenelli - Dec 15, 2021 Form 4 Insider Report for Dicerna Pharmaceuticals Inc (DRNA)

Role
Chief Strategy Officer
Signature
/s/ Douglas W. Pagan, attorney-in-fact
Stock symbol
DRNA
Transactions as of
Dec 15, 2021
Transactions value $
-$47,220
Form type
4
Date filed
12/17/2021, 03:18 PM
Previous filing
Dec 14, 2021
Next filing
Dec 29, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DRNA Common Stock Options Exercise +3.43K +27.12% 16.1K Dec 15, 2021 Direct F1
transaction DRNA Common Stock Tax liability -$47.2K -1.24K -7.73% $38.05 14.8K Dec 15, 2021 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DRNA Restricted Stock Units Options Exercise $0 -3.43K -25% $0.00 10.3K Dec 15, 2021 Common Stock 3.43K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Common Stock.
F2 Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs.
F3 The RSUs vest over a period of four years, with 25% of the RSUs vesting on each of the first, second, third and fourth anniversaries of December 15, 2020, subject in each case to the Reporting Person's continued employment or service with the Issuer through the applicable vesting date.